Site Editors

Alexander Drilon, MD

Gregory J. Riely, MD, PhD



Next-Generation TRK Inhibitor Under Study in NTRK Fusion–Positive Solid Tumors
Acquired Resistance to Entrectinib in Pancreatic Neuroendocrine Tumor: Case Report
What Do Head and Neck Mesenchymal Tumors With Kinase Fusions Look Like Histologically?
Optimizing the Detection of NTRK Fusion–Related Cancers: A Canadian Study
Applying Radiogenomics in Oncology: Another Step Toward Precision Medicine in the Clinic
NTRK Gene Fusions and TRK Protein Expression in Merkel Cell Carcinoma
FDA Approves Companion Diagnostic for Entrectinib in Treatment of NTRK Fusion–Positive Tumors
Use of Entrectinib in Lung Adenocarcinoma Harboring EML4::NTRK3 Gene Fusion: Case Report
NTRK Gene Fusions: Therapeutic Target in NF1-Linked Peripheral Nerve Sheath Tumors?
FDA Brief: New Guidance for Industry on Tissue-Agnostic Drug Development
Rechallenge With Osimertinib Plus Entrectinib in Lung Cancer With NTRK Fusion: Case Report
Are Kinase Inhibitors the Future for Patients With Refractory Thyroid Cancer?
Prevalence of NTRK Gene Fusions in a Real-World Canadian Setting
Detecting NTRK Gene Fusions in Metastatic Triple-Negative Breast Cancer: Case Report
Research Focuses on Identifying Genetically Matched Therapies for Salivary Gland Cancer
5 Years After Larotrectinib Treatment, MSK Patient Celebrates First Day of Kindergarten
Larotrectinib, Entrectinib, and Metastatic Cancers With NTRK Gene Fusion: Focus on Partitioned Survival Modeling
Can Semiconductor Sequencing Be of Use in Detecting Actionable Fusions in Solid Tumors?
Profiling Patients With NTRK Gene Fusion–Positive Cancer: UK Genomes Project
By continuing to browse this site you permit us and our partners to place identification cookies on your browser and agree to our use of cookies to identify you for marketing. Read our Privacy Policy to learn more.